![Marine One is the call sign of any United States Marine Corps aircraft carrying the President of the United States.[1] It usually denotes a helicopter operated by Marine Helicopter Squadron One (HMX-1 "Nighthawks"), either the large Sikorsky SH-3 Sea King or the newer, smaller VH-60N "White Hawk". A](/images/98af17d59404c1e7.jpg)
After Supreme Court Rebuke, Trump Uses Section 232 to Impose Up to 100% Tariffs on Some Patented Drug Imports and Adjust Steel/Aluminum Product Duties
Citing national‑security authority under Section 232, the administration has imposed tariffs of up to 100% on certain patented brand‑name pharmaceutical imports under a tiered regime—100% for products listed in Annex I, 20% for firms with Commerce‑approved onshoring plans (rising to 100% by 2030), and a zero‑tariff option for companies that both onshore production and sign Most‑Favored‑Nation pricing agreements under the TrumpRx initiative; generics and U.S.‑origin drugs are excluded “at this time,” and preferential rates (e.g., 15% for Japan/EU/South Korea/Switzerland, 10% for the U.K.) are provided for some allies. The tariffs (phased in for some firms on July 31 and others on Sept. 29, 2026) come alongside adjustments to duties on products containing steel and aluminum and mark the first expansion of duties since the Supreme Court partially struck down his earlier broad tariff program in February.
📌 Key Facts
- President Trump is imposing tariffs as high as 100% on certain imported patented (name‑brand) pharmaceuticals under a Section 232 national‑security proclamation; a senior administration official called the 100% level a "100% tax" on drugs made abroad.
- News outlets report the measure as an imposed policy (not merely a proposal) with specific effective dates: tariffs begin applying July 31, 2026 for some companies and September 29, 2026 for others.
- The administration is implementing a tiered tariff regime: a default 100% tariff on products listed in Annex I; a 20% tariff for companies with Commerce Department‑approved onshoring plans (rising to 100% by 2030); and a zero‑tariff option for firms that onshore production and sign "Most‑Favored‑Nation" pricing agreements under the TrumpRx initiative.
- The plan includes differentiated rates for certain allies: 15% for covered products from Japan, the European Union, South Korea and Switzerland, and 10% for products from the United Kingdom, with the possibility of future reductions to zero under agreements.
- Generic drugs and pharmaceuticals of U.S. origin are explicitly excluded from these tariffs "at this time," narrowing the immediate scope to patented brand‑name products and key ingredients.
- The administration cited quantitative context to justify the national‑security rationale: roughly 53% of patented pharmaceutical products distributed in the U.S. are produced abroad, while about 15% of patented active pharmaceutical ingredients (by volume) are made domestically.
- The move follows a partial Supreme Court rebuke in February that struck down the administration's earlier broad tariff program; this action is the first expansion or reapplication of duties since that decision. The administration also said it is "adjusting" tariffs on products that contain steel and aluminum.
📊 Relevant Data
Racial and ethnic disparities in prescription drug utilization and spending persist in the US, with Black and Hispanic individuals showing underutilization of medicines compared to White individuals across payer types and health status.
Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, and Health Status in the US, 2016-2021 — JAMA Health Forum
Socioeconomic inequalities account for a large share of the greater prescription drug cost burden experienced by older non-Hispanic Black and Hispanic/Latino adults in Medicare.
Racial and Ethnic Inequities in Managing Prescription Drug Costs Among Older Adults in Medicare — ResearchGate
US pharmaceutical manufacturing has been outsourced abroad primarily due to lower production costs, including labor and regulatory expenses in countries like China and India, leading to vulnerabilities in supply chains.
Rebuilding Resilience in U.S. Pharmaceutical Manufacturing — Center for Strategic and International Studies (CSIS)
Tariffs on pharmaceuticals could increase US drug prices by raising costs for imported ingredients and supplies, potentially leading to an annual increase of up to $51 billion in national drug costs under a 25% tariff scenario.
The Impact of U.S. Tariffs on the Pharmaceutical Industry and Healthcare Costs — PMC
Trump administration tariffs in 2025 led to a loss of 108,000 manufacturing jobs in the US during the first year, with declines in most sub-sectors despite aims to boost employment.
Tracking the Economic Effects of Tariffs — The Budget Lab at Yale
📰 Source Timeline (4)
Follow how coverage of this story developed over time
- The Fox article spells out a tiered tariff regime for patented pharmaceutical imports: a default 100% tariff on products listed in Annex I, a 20% tariff for companies with Commerce Department–approved onshoring plans (rising to 100% in 2030), and a zero-tariff option for firms that both onshore production and sign 'Most-Favored-Nation' pricing agreements under the TrumpRx initiative.
- It details differentiated tariff rates for specific allies: 15% for covered products from Japan, the European Union, South Korea and Switzerland, and 10% for those from the United Kingdom, with potential reductions to zero under future agreements.
- The article clarifies that generic pharmaceuticals and U.S.-origin drugs are explicitly excluded from these tariffs "at this time," narrowing the policy’s immediate scope to patented, brand-name products and their key ingredients.
- The piece provides quantitative context that about 53% of patented pharmaceutical products distributed in the U.S. are produced abroad, while only 15% of patented active pharmaceutical ingredients by volume are made domestically, numbers Trump uses to justify the move as a national-security measure.
- It specifies effective dates: tariffs begin to apply on July 31, 2026, for some companies and September 29, 2026, for others, and confirms the legal hook is a Section 232 national security proclamation, with a senior official characterizing the 100% level as a '100% tax' on drugs made abroad.
- PBS states that 'the president is imposing a 100% tariff on some imported pharmaceuticals,' indicating the tariffs have taken effect rather than remaining a proposal.
- The segment frames the pharmaceutical tariffs explicitly in the context of the day’s headlines, reinforcing that this is an active policy step, not just a floated idea.
- No new product list or implementation date is provided, but the language confirms the status as an imposed measure.
- Trump announced he will levy tariffs as high as 100% on some name‑brand pharmaceuticals.
- He also said the administration is 'adjusting' tariffs on products that contain steel and aluminum.
- The article notes this is the first move to expand duties since the Supreme Court partially struck down his earlier broad tariff program in February.